Literature DB >> 1597164

The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone.

N Kumar1, A K Didolkar, C Monder, C W Bardin, K Sundaram.   

Abstract

Based on the premise that testosterone, but not 7 alpha-methyl-androgens, is reduced at the 5 alpha-position in the prostate and seminal vesicles, the differential bioactivities of these androgens were investigated in castrated rats. The ability of 7 alpha-methyl-19-nortestosterone acetate (MENT) to increase the weights of ventral prostate and seminal vesicles of castrated rats was four times higher than that of testosterone, while its effect on the weights of bulbocavernosus plus levator ani muscles (muscle), was 10 times that of testosterone. MENT was also approximately 12 times more potent than testosterone in the suppression of serum gonadotropin levels. A dose of testosterone that maintains serum gonadotropin levels and muscle mass also maintains prostate and seminal vesicle weights in castrated rats. By contrast, a dose of MENT that maintains muscle and gonadotropins does not maintain prostate and seminal vesicles. The action of other 7 alpha-methylated androgens were similar to that of MENT. The importance of 5 alpha reductase in the differential action of testosterone and MENT on prostate was confirmed by using a 5 alpha-reductase inhibitor. The activity of testosterone was significantly suppressed in the ventral prostate and seminal vesicles but not on muscle by the 5 alpha-reductase inhibitor (N,N-diethyl-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide). The enzyme inhibitor, however, had no influence on the activity of MENT on either tissue. In contrast, cyproterone acetate, an antiandrogen that competitively binds to the androgen receptors, inhibited the action of MENT and of testosterone on the prostate as well as on the muscle. In conclusion, these observations show that 7 alpha-methylated androgens can maintain muscle mass and normal gonadotropin levels in androgen deficient rats without hyperstimulating the prostate. These findings suggest that 7 alpha-methylated androgens may offer some health benefits to men who require androgen treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1597164     DOI: 10.1210/endo.130.6.1597164

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  18 in total

1.  Differential regulation of testosterone vs. 5alpha-dihydrotestosterone by selective androgen response elements.

Authors:  P W Hsiao; T H Thin; D L Lin; C Chang
Journal:  Mol Cell Biochem       Date:  2000-03       Impact factor: 3.396

Review 2.  Hormonal replacement therapy.

Authors:  Regine Sitruk-Ware
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 3.  Discovery and therapeutic promise of selective androgen receptor modulators.

Authors:  Jiyun Chen; Juhyun Kim; James T Dalton
Journal:  Mol Interv       Date:  2005-06

Review 4.  Prospects for pharmacological male contraception.

Authors:  S A Matlin
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

5.  The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects.

Authors:  Barbara J Attardi; Sheri A Hild; Sailaja Koduri; Trung Pham; Laurent Pessaint; Jean Engbring; Bruce Till; David Gropp; Anne Semon; Jerry R Reel
Journal:  J Steroid Biochem Mol Biol       Date:  2010-06-25       Impact factor: 4.292

6.  Cloning and characterization of TDD5, an androgen target gene that is differentially repressed by testosterone and dihydrotestosterone.

Authors:  T M Lin; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

7.  'Andropause'--are reduced androgen levels in aging men physiologically important?

Authors:  A M Matsumoto
Journal:  West J Med       Date:  1993-11

Review 8.  Contraception technology: past, present and future.

Authors:  Regine Sitruk-Ware; Anita Nath; Daniel R Mishell
Journal:  Contraception       Date:  2012-09-17       Impact factor: 3.375

9.  7α-methyl-19-nortestosterone vs. testosterone implants for hypogonadal osteoporosis: a preclinical study in the aged male orchidectomized rat model.

Authors:  M Sinnesael; F Callewaert; M Morreels; N Kumar; R Sitruk-Ware; K Van Proeyen; P Hespel; S Boonen; F Claessens; D Vanderschueren
Journal:  Int J Androl       Date:  2011-07-26

Review 10.  Androgen replacement therapy: present and future.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.